In October 2009, Arzerra (ofatumumab) received accelerated approval from the FDA for use in patients with chronic lymphocytic leukemia (CLL) that is refractory to treatment with fludarabine and alemtuzumab. The drug is being commercialized by GlaxoSmithKline under a global license from Genmab. Arzerra is a monoclonal antibody (MAb) that attaches to the small and large loop epitopes on CD20 found on the surface of B-cells, and recruits the body's natural defenses to attack and kill these selected cells that are implicated in cancer, and autoimmune and inflammatory diseases. Arzerra is one of several approaches currently in development for the treatment of CLL, an incurable hematologic malignancy (see http://www.ncbi.nlm.nih.gov/pubmed/19619273?itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum&ordinalpos=9). Arzerra is in development for other indications, mostly in combination with other approved agents.

Azatoxin, a hybrid of etoposide and ellipticine, originally proposed in the early 1990s, is back in the news as a more favorable cytotoxic alternative acting as a topoisomerase II inhibitor and a spindle poison. Certain azatoxin derivatives are 100 times more active than etoposide.
http://www.thefederalregister.com/d.p/2009-04-23-E9-9344